Related references
Note: Only part of the references are listed.Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity
Valentina Masola et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities
Anne-Christine Piguet et al.
CLINICAL SCIENCE (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Vertical blockade of the IGFR-PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
Da-Liang Ou et al.
MOLECULAR CANCER (2014)
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review
Evangelos Cholongitas et al.
TRANSPLANT INTERNATIONAL (2014)
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
Goran B. Klintmalm et al.
JOURNAL OF TRANSPLANTATION (2014)
Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
Gianluigi Zaza et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase
Xuefeng Xu et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2013)
Adverse events associated with mTOR inhibitors
Nicolas Pallet et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase
Valentina Masola et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis
Kenya Yamanaka et al.
CANCER MEDICINE (2013)
Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma
Laia Rosich et al.
CLINICAL CANCER RESEARCH (2012)
TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion
Samy Lamouille et al.
JOURNAL OF CELL SCIENCE (2012)
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
Nicole Grabinski et al.
MOLECULAR CANCER (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
Camillo Porta et al.
EUROPEAN JOURNAL OF CANCER (2011)
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia
Peter J. Bugelski et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2010)
Pneumonitis Associated With Mammalian Target of Rapamycin Inhibitors in Renal Transplant Recipients: A Single-Center Experience
P. Errasti et al.
TRANSPLANTATION PROCEEDINGS (2010)
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
X. B. Trinh et al.
BRITISH JOURNAL OF CANCER (2009)
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9
Jing-song Chen et al.
HEPATOLOGY RESEARCH (2009)
Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge
F. van Zijl et al.
ONCOGENE (2009)
Management of Side Effects of Sirolimus Therapy
Giovanni Stallone et al.
TRANSPLANTATION (2009)
Sirolimus and Everolimus Induced Pneumonitis in Adult Renal Allograft Recipients: Experience in a Center
A. Rodriguez-Moreno et al.
TRANSPLANTATION PROCEEDINGS (2009)
mTOR, cancer and transplantation
Edward K. Geissler et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
Magnus Rizell et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Severe everolimus-associated pneumonitis in a renal transplant recipient
Simona Alexandru et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Proliferation signal inhibitors in transplantation: Questions at the cutting edge of everolimus therapy
J. R. Chapman et al.
TRANSPLANTATION PROCEEDINGS (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis
Markus Neef et al.
JOURNAL OF HEPATOLOGY (2006)
Liver biopsy interpretation for causes of late liver allograft dysfunction
Anthony J. Demetris et al.
HEPATOLOGY (2006)
Akt signaling and cancer: Surviving but not moving on
A Toker et al.
CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
G Stallone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Immunosuppression: towards a logical approach in liver transplantation
I Perry et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Effects of lipopolysaccharides stimulated Kupffer cells on activation of rat hepatic stellate cells
Xin Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
E Morelon et al.
TRANSPLANTATION (2001)
Share Paper
